Article: Santen Receives FDA Approval of ALAMAST, Anti-Allergy Eye Drops.

OSAKA, Japan--(BW HealthWire)--Sept. 24, 1999--

Santen Pharmaceutical Co., Ltd., President and CEO Takakazu Morita, announced today that it has received approval for its NDA (New Drug Application) submitted on March 26, 1999, from the U.S. Food and Drug Administration for its new ocular allergy medication ALAMAST(TM) (pemirolast potassium) 0.1%, indicated for the prevention of itch due to allergic conjunctivitis.

Santen's Napa, California-based subsidiary, Santen Incorporated will launch ALAMAST in the U.S. ophthalmic market in 2000.

"We're looking forward to introducing Santen's first product in the U.S.," says Santen Inc. President and CEO ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!